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compare the costs and outcomes of azacitidine (75 mg/m2 per day x 7 days every 4
weeks) vs. decitabine (45 mg/m2 per day x 3 days every 6 weeks) from the perspec-
tive of SUS. METHODS: We developed a Markov model to determine the cost-
effectiveness (CE) and 3-year budget impact of introducing AZA in the Brazilian
market. Patients considered were classified with IPSS Int 1, Int 2 and High risk. The
model considered progression to acute myelogenous leukemia (AML) and death as
the major outcomes of treatment. Outcomes, costs and epidemiological data were
obtained from a systematic review of literature and public sources. The costs of
adverse events and progressive disease were also included. A sensitivity analysis
was performed to test the robustness of the results. The currency conversion used
was BR$ 1.8: US$1.0. RESULTS: The cost effectiveness analysis showed better re-
sults for AZA compared to DEC resulting in lower costs and improved outcomes in
terms ofmortality rates and progression to AML. Over a 3-year time period, the use
of AZA was associated with a savings of BR$85,000 (US$45,000) compared to DEC.
Assuming that AZA would be given to 50% of patients with MDS in Brazil, it would
have a budgetary impact of BR$45,000 000 (US$25,000,000) for the public health care
system SUS. CONCLUSIONS:When compared to DEC, AZA showed improved out-
comes and lower costs as a treatment option for MDS in the Brazilian public health
system.
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OBJECTIVES: To estimate resource use, costs, and adverse events (AEs) among lung
cancer (LC) patients on standard chemotherapy with versus without an angiogen-
esis inhibitor (AGI) as adjunctive therapy. METHODS: Using Thompson Reuters
MarketScan®ResearchDatabase, patientswith a diagnosis code indicating primary
LC between 2005 and 2009 and at least one claim for an FDA approved AGI (bevaci-
zumab) within 8 days of chemotherapywere identified (AGI cohort). These patients
were matched 1:1 by demographics, cancer characteristics, and previous chemo-
therapy failure (30 days without chemotherapy) to patients on chemotherapy
with no claims for an AGI (No-AGI cohort). Patients were followed for 1 month.
All-cause per-patient-per-month (PPPM) resource use (inpatient, ER, and outpa-
tient), costs (in 2010 USD), and the prevalence of AEs were assessed. RESULTS: A
total of 766 patients were identified for each cohort (mean age 57.5 years, 47.9%
female). Mean follow-up was 10.4 and 11.6 months in the AGI and No-AGI cohorts.
All components of resource usewere similar between cohorts. All-cause total PPPM
cost was higher for the AGI cohort ($16,972 vs. $11,950 PPPM), primarily due to
higher outpatient infusion costs ($7,703 vs. $1,423). Over 52% of patients in each
cohort had 1 AE, and there were no statistically-significant differences in the
prevalence of AEs between groups. Themost common AEs were infusion reactions
(40.6% in AGI vs. 39.7% in No-AGI), dyspnea, (38.1% vs. 43.0%), nausea (37.6% vs.
33.8%), dehydration (32.9% vs. 34.1%), chest pain (28.9% vs. 31.5%), anemia (26.1%
vs. 24.4%), neutropenia (24.9% vs. 24.7%), thromboembolic events (17.2% vs. 20.6%),
and hemorrhage (15.4% vs. 12.7%). CONCLUSIONS: Prevalence of AEs was not sig-
nificantly different among LC patients on chemotherapy with and without an AGI.
Costs were higher in the AGI cohort, due to higher infusion costs. Future studies of
the cost-effectiveness of AGIs in LC patients based on real-world data are war-
ranted.
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OBJECTIVES:We performed an indirect comparison of efficacy and safety data for
two combination chemotherapy regimens (pemetrexed/cisplatin [PC] and bevaci-
zumab/cisplatin/gemcitabine [BCG]) approved for the first-line treatment of ad-
vanced, non-squamous non-small cell lung cancer (NSCLC). Our objectives were to
compare the survival outcomes and approximate mean incremental costs in
México for these two approved regimens using data from two phase III trials with a
common comparator (cisplatin/gemcitabine [CG]). METHODS: An indirect treat-
ment comparison was conducted using the Bucher method. One study compared
CG with BCG and included two doses of bevacizumab, but only the data for the 7.5
mg/kg dose of bevacizumabwas included in our analysis because this dose ismore
commonly used for NSCLC in México. The cost analysis included the estimated
costs of chemotherapy and costs related to the treatment of grade 3 or 4 adverse
events. Total chemotherapy drug costs were based on the mean number of cycles
of chemotherapy delivered in the two studies. Costs were calculated in 2011 Mex-
ican pesos and converted to US dollars. RESULTS: Significantly fewer patients ex-
perienced a grade3 adverse event with PC than BCG (risk difference: -10.50%; 95%
confidence interval [CI]: -18.4 to -2.71, p0.008). Overall survival was not signifi-
cantly different for PC vs BCG (hazard ratio [HR]0.87, 95% CI: 0.69 to 1.10, p0.242),
although in the individual trials PC had a significant survival advantage over CG
(HR0.84; 95% CI: 0.74 to 0.96, p0.011) while BCG (7.5 mg/kg bevacizumab) had no
survival advantage (HR0.93; 95% CI: 0.78 to 1.11. p0.420). The total estimated
costs were $20212 lower for PC than BCG. The cost savings for the PC regimenwere
predominantly due to lower pharmacy-related drug costs ($10501 vs $30121).
CONCLUSIONS: PChad lower estimated costs and less serious toxicity compared to
BCG and produced at least comparable survival outcomes.
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OBJECTIVES: The National Cancer Institute (NCI) estimates that cancer accounted
for approximately $124.57 billion dollars in direct costs in the United States in 2010.
NCI provides costs estimates on the initial, continuing and last ‘phase of care’ but
does not provide a breakdown by stage. This study aims to describe the costs
associated with stage 3 (S3) and stage 4 (S4) colon cancer (CC). METHODS: Data
from 1997-2005 of the Surveillance, Epidemiology, and End-Result-Medicare data-
set was used for this analysis. Individuals includedwere those diagnosed as having
AJCC S3 or S4 CC. Analyses excluded individuals whowere not eligible forMedicare
Parts A and B or those insured by Medicare HMO. Areas under the curve (AUC) for
direct medical costs were summed over a 40 week period, from time of CC diagno-
sis. Costs contributed were from beneficiaries who died from S3 and S4 CC and
were ever treated with chemotherapy. Costs were summed for S3 and S4 individ-
uals with at least 26 weeks of initial chemotherapy treatment. RESULTS: These
analyses identified 3549 individuals with S3 CC and 8194 individuals with S4 CC.
Over the 40 week observation period, the AUC for S3 and S4 CC was $52,145, and
$45,106, respectively. Meanweekly costs peaked at week 31 for S3 CC ($3425) and at
week 29 for S4 CC ($1,725). Among S3 and S4 individuals with at least 26 weeks of
initial chemotherapy treatment, the AUC was $35,890 for S3 CC and $49,871 for S4
CC. CONCLUSIONS: Among individuals who died with S3 or S4 CC and were ever
treated with chemotherapy, the costs associated with S3 cancer exceed those of S4
cancer over the 40 week observation period. Among those with at least 26 weeks of
initial chemotherapy and treatment, S3 chemotherapy treatment is less expensive
than S4 chemotherapy treatment.
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OBJECTIVES: This retrospective claims analysis aimed to compare erythropoiesis-
stimulating agent (ESA) dosing patterns and costs in chemotherapy-induced ane-
mia (CIA) hospital outpatients. METHODS: Electronic records from the Premier
hospital database (2006Q1-2011Q1) were used to identify outpatients aged 18
years that had a diagnosis for cancer, received chemotherapy during hospitaliza-
tion, and received epoetin alfa (EPO) or darbepoetin alfa (DARB).Exclusion criteria
were: a diagnosis of chronic kidney disease, diagnosis of myelodysplastic syn-
drome, receipt of renal dialysis, or receipt of both ESAs. The observation period
consisted of the outpatient continuous ESA episode, defined as the period fromfirst
to last outpatient visit with ESA use without a gap of more than one calendar
month between ESA visits. The ESA dose ratio (Units EPO: mcg DARB) was calcu-
lated using the mean cumulative dose of EPO and DARB. ESA treatment costs were
determined using cumulative dose and December 2010 wholesale acquisition
costs. RESULTS: A total of 7413 outpatient ESA episodes (EPO: 3979; DARB: 3434)
were identified. The EPO group had a lower proportion of females versus the DARB
group (61.7% vs. 67.7%, respectively; P0.001), however, EPO and DARB groups had
a similar mean age (62.0 vs. 61.8 years, respectively; P0.560) and duration of out-
patient episode (2.3months for both, P0.738). Themean cumulative dosewas EPO
212,752 Units and DARB 998mcg, resulting in a dose ratio (Units EPO: mcg DARB) of
213:1. Correspondingmean ESA treatment costs were higher for DARB than for EPO
(EPO: $3,223 vs. DARB: $5,352, P0.001). CONCLUSIONS: In this analysis of CIA
hospital outpatient records, a dose ratio (Units EPO: mcg DARB) of 213:1 was ob-
served. Mean ESA treatment costs were observed to be approximately 66% higher
for the DARB group than for the EPO group.
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OBJECTIVES: This retrospective analysis aimed to compare erythropoiesis-stimu-
lating agent (ESA) dosing patterns and costs in chemotherapy-induced anemia
(CIA) inpatients.METHODS: Electronic records from the Premier hospital database
(2006Q1-2011Q1) were used to identify inpatients aged 18 years that had a diag-
nosis for cancer, received chemotherapy during hospitalization, and received epo-
etin alfa (EPO) or darbepoetin alfa (DARB). Exclusion criteria were: a diagnosis of
chronic kidney disease, diagnosis of myelodysplastic syndrome, receipt of renal
dialysis, or receipt of both ESAs. The observation period consisted of the inpatient
stay. The ESA dose ratio (Units EPO: mcg DARB) was calculated using the mean
cumulative dose of EPO and DARB. ESA treatment costs were determined using
cumulative dose and December 2010wholesale acquisition costs. RESULTS:A total
of 20,132 inpatient stays (EPO: 15,221; DARB: 4,911) were identified. The EPO group
was older than the DARB group (65.0 vs. 63.7 years, respectively; P0.001), had a
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